Pharmaceuticals Global On demand · 24-48h

Global Cannabis Pharmaceuticals Market Strategic Research Report

Global Cannabis Pharmaceuticals Market Strategic Research Re…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Cannabis Pharmaceuticals Market
$1.45B2025
14.3%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Sprays, Capsules, Tablets, Others

By Application: Pharmacies, Hospitals, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Cronos Group, Jazz Pharmaceuticals, Elixinol Wellness, Trulieve, Tilray Brands, Inc., Cansortium Inc., Aurora Cannabis, Canopy Growth, Cresco Labs, Organigram

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 103 pages
Market size 2025
$1.45B
Billion USD
Forecast CAGR
14.3%
2025-2032
Forecast 2032
$3.7B
Projected
区域
5
Asia Pacific · Latin America · MEA · Europe · North America

概述

Scope of the Report

The global Cannabis Pharmaceuticals market size is predicted to grow from US$ 1,451 million in 2025 to US$ 3,639 million in 2032; it is expected to grow at a CAGR of 14.3% from 2026 to 2032.

Cannabis pharmaceuticals refers to the development and sale of pharmaceutical drugs or medicines with compounds of cannabis plants acting as key components. The plant belongs to the Cannabaceae family of flowering plants and produces a highly popular psychoactive drug called marijuana or cannabis. The plant is indigenous to South and Central Asia. It is widely used as a recreational drug. However, in recent times, the pharmaceutical industry has invested heavily in exploring the plant and its components for their medicinal attributes. Two of the most well-researched and popular components are cannabidiol (CBD) and tetrahydrocannabinol (THC) since they are known to exhibit several therapeutic effects. Cannabis pharmaceuticals deal with exploring a combination of cannabinoids and studying their impact on diseases or health conditions under a controlled environment and in the guidance of a licensed supervisor such as a medical practitioner. Medicines produced using cannabis are available in several forms including sprays, capsules, and tablets. The medicines cannot be rolled out in the commercial market without receiving necessary approvals from regulatory bodies.

Global key Cannabis Pharmaceuticals players cover Cronos Group, Jazz Pharmaceuticals, Elixinol Wellness, Trulieve, Tilray Brands, Inc., etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Cannabis Pharmaceuticals market?

What factors are driving Cannabis Pharmaceuticals market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Cannabis Pharmaceuticals market opportunities vary by end market size?

How does Cannabis Pharmaceuticals break out by Type, by Application?

This report presents a comprehensive overview of the global Cannabis Pharmaceuticals market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Sprays
  • Capsules
  • Tablets
  • Others

Segment by Application

  • Pharmacies
  • Hospitals
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Cannabis Pharmaceuticals market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Pharmacies, Hospitals, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Cannabis Pharmaceuticals Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 14.3%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.45B
2025
Forecast
$3.7B
2032
CAGR
14.3%
2025–2032
区域
5
global
Key companies
Cronos GroupJazz PharmaceuticalsElixinol WellnessTrulieveTilray Brands, Inc.Cansortium Inc.Aurora CannabisCanopy Growth
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
SpraysCapsulesTabletsOthers
By Application
PharmaciesHospitalsOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Sprays
  • 3.1.3 Capsules
  • 3.1.4 Tablets
  • 3.1.5 Others
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Pharmacies
  • 4.1.3 Hospitals
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Cronos Group
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Jazz Pharmaceuticals
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Elixinol Wellness
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Trulieve
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Tilray Brands, Inc.
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Cansortium Inc.
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Aurora Cannabis
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Canopy Growth
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Cresco Labs
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Organigram
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Cannabis Pharmaceuticals market?
The global Cannabis Pharmaceuticals market is estimated at US$ 1.45 billion in 2025 (base year) and is projected to reach US$ 3.64 billion by 2032.
What is the forecast CAGR for the Cannabis Pharmaceuticals market?
The market is expected to grow at a CAGR of 14.3% from 2026 to 2032, expanding from US$ 1.45 billion in 2025 to US$ 3.64 billion in 2032, roughly 2.5 times its base-year value.
What is Cannabis Pharmaceuticals?
Cannabis pharmaceuticals refers to the development and sale of pharmaceutical drugs or medicines with compounds of cannabis plants acting as key components. The plant belongs to the Cannabaceae family of flowering plants and produces a highly popular psychoactive drug called marijuana or cannabis. The plant is indigenous to South and Central Asia.
What are the main segments of the Cannabis Pharmaceuticals market by type?
By type, the market is segmented into Sprays, Capsules, Tablets and Others.
Which applications drive demand in the Cannabis Pharmaceuticals market?
Key applications covered include Pharmacies, Hospitals and Others.
Who are the key players in the Cannabis Pharmaceuticals market?
Key players profiled include Cronos Group, Jazz Pharmaceuticals, Elixinol Wellness, Trulieve, Tilray Brands, Cansortium Inc., Aurora Cannabis and Canopy Growth, among 10 companies covered in total.
Which regions and countries are covered for Cannabis Pharmaceuticals?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Cannabis Pharmaceuticals market?
What factors are driving Cannabis Pharmaceuticals market growth, globally and by region?
Who should buy the Cannabis Pharmaceuticals market report?
The report is intended for manufacturers and solution providers, distributors and end users in Pharmacies, Hospitals and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Cannabis Pharmaceuticals market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from US$3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.